LogicBio Therapeutics
65 Hayden Ave.
Lexington
Massachusetts
02421
United States
Tel: 781-771-5579
Website: http://www.logicbio.com/
Email: contact@logicbio.com
96 articles about LogicBio Therapeutics
-
Shares of LogicBio Therapeutics have fallen more than 57% this morning after the company announced that its gene therapy for pediatric patients with methylmalonic acidemia has been placed on clinical hold by the U.S. Food and Drug Administration.
-
LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference
1/4/2022
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference being held January 10-13, 2022.
-
LogicBio Therapeutics Provides Business Updates
12/22/2021
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial and development pipeline, and announced the appointment of Susan R. Kahn to its Board of Directors.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
11/15/2021
LogicBio Therapeutics, Inc., a clinical-stage genetic medicine company, reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate milestones.
-
LogicBio Therapeutics to Participate in Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
LogicBio Therapeutics, Inc., a clinical-stage genetic medicine company, announced that president and chief executive officer, Frederic Chereau, will participate at the following upcoming investor conferences.
-
LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using GeneRide™ Genome Editing Technology
10/21/2021
LogicBio Therapeutics, Inc. today is slated to present new preclinical data on its GeneRide™ platform at the European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, taking place October 19-22, 2021.
-
The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis.
-
On Monday, LogicBio Therapeutics unveiled clinical trial results demonstrating the first-ever in vivo, nuclease-free genome editing in little humans.
-
LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
10/18/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever in vivo genome editing in children.
-
LogicBio Therapeutics to Present New GeneRide™ Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
10/12/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), today announced that it was selected to present new data from the company's GeneRide™ platform in a plenary oral presentation and three poster presentations at the upcoming European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021.,
-
LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
9/24/2021
LogicBio Therapeutics, Inc. today announced that president and chief executive officer, Fred Chereau , will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 8:00 a.m. ET.
-
LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/10/2021
LogicBio Therapeutics, Inc. today announced that president and chief executive officer Fred Chereau will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.
-
LogicBio Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones
8/9/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate milestones.
-
LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021
7/8/2021
LogicBio Therapeutics, Inc. today announced that Frederic Chereau , chief executive officer of LogicBio, will participate in a virtual panel discussion entitled "Delivery and Durability of Genetic Medicines" at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET.
-
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia
6/2/2021
Company remains on track to announce update on enrollment, dose escalation and age de-escalation in late 2021 and interim data by year-end 2021
-
LogicBio Therapeutics to Participate in Upcoming Investor Conferences
6/1/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in virtual fireside chats at the following upcoming investor conferences
-
BioSpace Movers & Shakers, May 21
5/21/2021
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. -
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments
5/19/2021
- Stephen Boyer joined company as vice president, regulatory and quality affairs and Peter Pechan joined as vice president, gene therapy
-
BioSpace Movers & Shakers, May 14
5/14/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.